FDA Panel Shoots Down Oscient Request
A panel of the U.S. Food and Drug Administration said Tuesday that Oscient Pharmaceuticals Corp. had not proved its Factive drug is safe and effective enough to use for the treatment...To view the full article, register now.
Already a subscriber? Click here to view full article